Washington: CellMax Life, a precision cancer blood-testing company, on Wednesday announced the availability of CellMax-LBx Liquid Biopsy in India.
CellMax-LBx is a cancer blood test that analyses circulating tumour DNA (ctDNA). The assay provides oncologists with a valuable tool in managing their patients’ cancer treatments, monitoring treatment response, and assessing the risk of recurrence, according to a statement.
CellMax-LBx is intended as a supplement to a tissue biopsy, and as an alternative when tissue biopsy is not possible. The test profiles 73 genes from circulating tumour DNA (ctDNA) to identify and assess actionable genomic alterations using CellMax Life’s single-molecule-sequencing SMSEQ platform.
Circulating tumour DNAs (ctDNAs) are small DNA fragments shed by the tumour. Tumour genes may mutate over time, either as the cancer grows, or the treatment suppresses the cancer. ctDNA gives an accurate, real-time picture of these cancer mutations, the statement said.
“The incidence of cancer is expected to increase by 70% over the next two decades. CellMax Life’s goal is to reduce cancer mortality by empowering patients and their doctors to make the most informed health decisions possible, with the necessary frequency,” said Rui Mei, chief scientific officer, CellMax Life.